Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CLYM NASDAQ:DRUG NASDAQ:DSGN NYSE:PLX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLYMClimb Bio$12.84+0.6%$12.01$1.36▼$14.41$730.68M0.071.47 million shs665,913 shsDRUGBright Minds Biosciences$71.33+0.1%$71.91$31.80▼$123.75$694.20M-5.34267,142 shs345,923 shsDSGNDesign Therapeutics$11.78+1.3%$12.33$3.76▼$17.25$735.74M1.58886,532 shs417,080 shsPLXProtalix BioTherapeutics$2.37$2.19$1.41▼$3.19$190.96MN/A960,003 shs212,184 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLYMClimb Bio+0.63%+1.10%+0.71%+40.48%+767.57%DRUGBright Minds Biosciences+0.06%-6.29%+7.72%-20.00%+138.72%DSGNDesign Therapeutics+1.29%-6.28%-14.51%-5.99%+175.88%PLXProtalix BioTherapeutics0.00%-0.42%+5.80%+8.72%+48.13%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLYMClimb Bio$12.84+0.6%$12.01$1.36▼$14.41$730.68M0.071.47 million shs665,913 shsDRUGBright Minds Biosciences$71.33+0.1%$71.91$31.80▼$123.75$694.20M-5.34267,142 shs345,923 shsDSGNDesign Therapeutics$11.78+1.3%$12.33$3.76▼$17.25$735.74M1.58886,532 shs417,080 shsPLXProtalix BioTherapeutics$2.37$2.19$1.41▼$3.19$190.96MN/A960,003 shs212,184 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLYMClimb Bio+0.63%+1.10%+0.71%+40.48%+767.57%DRUGBright Minds Biosciences+0.06%-6.29%+7.72%-20.00%+138.72%DSGNDesign Therapeutics+1.29%-6.28%-14.51%-5.99%+175.88%PLXProtalix BioTherapeutics0.00%-0.42%+5.80%+8.72%+48.13%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLYMClimb Bio 3.07Buy$21.7369.22% UpsideDRUGBright Minds Biosciences 3.14Buy$143.83101.64% UpsideDSGNDesign Therapeutics 2.88Moderate Buy$16.5040.07% UpsidePLXProtalix BioTherapeutics 3.00Buy$12.00406.33% UpsideCurrent Analyst Ratings BreakdownLatest PLX, DSGN, DRUG, and CLYM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/21/2026DRUGBright Minds Biosciences Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy7/17/2026CLYMClimb Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/17/2026DSGNDesign Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/24/2026CLYMClimb Bio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.006/12/2026CLYMClimb Bio WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$17.006/11/2026CLYMClimb Bio BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$19.00 ➝ $20.006/8/2026CLYMClimb Bio GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$35.006/8/2026CLYMClimb Bio GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$35.006/8/2026CLYMClimb Bio BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$19.006/1/2026DRUGBright Minds Biosciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$145.005/20/2026DRUGBright Minds Biosciences Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$190.00 ➝ $220.00(Data available from 7/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLYMClimb BioN/AN/AN/AN/A$3.36 per shareN/ADRUGBright Minds BiosciencesN/AN/AN/AN/A$8.33 per shareN/ADSGNDesign TherapeuticsN/AN/AN/AN/A$3.73 per shareN/APLXProtalix BioTherapeutics$76.38M2.50$0.13 per share17.80$0.47 per share5.04Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLYMClimb Bio-$59.85M-$0.78N/AN/AN/AN/A-31.45%-30.39%8/11/2026 (Estimated)DRUGBright Minds Biosciences-$8.74M-$2.44N/AN/AN/AN/A-20.58%-20.25%8/13/2026 (Estimated)DSGNDesign Therapeutics-$69.79M-$1.20N/AN/AN/AN/A-33.07%-31.29%8/6/2026 (Estimated)PLXProtalix BioTherapeutics$8.31M$0.18N/A7.65N/A-21.03%-30.89%-11.74%N/ALatest PLX, DSGN, DRUG, and CLYM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2026Q3 2026DRUGBright Minds Biosciences-$1.2831N/AN/AN/AN/AN/A8/11/2026Q2 2026CLYMClimb Bio-$0.22N/AN/AN/AN/AN/A8/6/2026Q2 2026DSGNDesign Therapeutics-$0.36N/AN/AN/AN/AN/A5/20/2026Q2 2026DRUGBright Minds Biosciences-$0.8633-$0.80+$0.0633-$0.80N/AN/A5/7/2026Q1 2026CLYMClimb Bio-$0.26-$0.20+$0.06-$0.20N/AN/A4/28/2026Q1 2026DSGNDesign Therapeutics-$0.36-$0.29+$0.07-$0.29N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCLYMClimb BioN/AN/AN/AN/AN/ADRUGBright Minds BiosciencesN/AN/AN/AN/AN/ADSGNDesign TherapeuticsN/AN/AN/AN/AN/APLXProtalix BioTherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLYMClimb BioN/A27.8627.86DRUGBright Minds BiosciencesN/A81.4781.47DSGNDesign TherapeuticsN/A22.2822.28PLXProtalix BioTherapeuticsN/A1.981.27Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLYMClimb Bio69.76%DRUGBright Minds Biosciences40.52%DSGNDesign Therapeutics56.64%PLXProtalix BioTherapeutics16.53%Insider OwnershipCompanyInsider OwnershipCLYMClimb Bio2.60%DRUGBright Minds Biosciences42.66%DSGNDesign Therapeutics17.10%PLXProtalix BioTherapeutics6.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLYMClimb Bio957.26 million55.77 millionN/ADRUGBright Minds BiosciencesN/A9.73 million5.58 millionNot OptionableDSGNDesign Therapeutics4062.46 million51.78 millionOptionablePLXProtalix BioTherapeutics20080.57 million69.00 millionOptionablePLX, DSGN, DRUG, and CLYM HeadlinesRecent News About These CompaniesProtalix BioTherapeutics, Inc. Q1 2026 Earnings Call SummaryMay 15, 2026 | finance.yahoo.comPLX: Chiesi Milestone ReceivedMay 14, 2026 | finance.yahoo.comProtalix BioTherapeutics, Inc. (AMEX:PLX) Q1 2026 Earnings Call TranscriptMay 14, 2026 | insidermonkey.comTranscript: Protalix BioTherapeutics Q1 2026 Earnings Conference CallMay 14, 2026 | uk.finance.yahoo.comProtalix BioTherapeutics Inc (PLX) Q1 2026 Earnings Call Highlights: Strong Financial Position ...May 14, 2026 | finance.yahoo.comProtalix BioTherapeutics, Inc. (PLX) Q1 2026 Earnings Call TranscriptMay 13, 2026 | seekingalpha.comProtalix BioTherapeutics Reports First Quarter 2026 Financial and Business ResultsMay 13, 2026 | prnewswire.comProtalix BioTherapeutics to Announce First Quarter 2026 Financial Results and Business Update on May 13, 2026May 6, 2026 | prnewswire.comProtalix: Elfabrio Struggles Against Oral CompetitionApril 15, 2026 | seekingalpha.comProtalix Revenue Miss Overshadowed By Milestone-Backed 2026 GuidanceMarch 24, 2026 | seekingalpha.comProtalix BioTherapeutics, Inc.: Protalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business ResultsMarch 18, 2026 | finanznachrichten.deProtalix targets $78M–$83M 2026 revenue with EU milestone, advancing PRX-115March 18, 2026 | seekingalpha.comProtalix BioTherapeutics advances Fabry disease and gout programs during 2025March 18, 2026 | proactiveinvestors.comProtalix: Q4 Earnings SnapshotMarch 18, 2026 | finance.yahoo.comProtalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business ResultsMarch 18, 2026 | finance.yahoo.comProtalix BioTherapeutics and partner secure EU approval for new Fabry disease dosing regimenMarch 9, 2026 | proactiveinvestors.comChiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase ...March 9, 2026 | tmcnet.comChiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa)March 9, 2026 | globenewswire.comProtalix BioTherapeutics (PLX) price target decreased by 12.00% to 11.22February 4, 2026 | msn.comA March Decision That Could Change Protalix BioTherapeutics OutlookFebruary 1, 2026 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSK Hynix’s Nasdaq Listing Could Reset the AI Memory TradeBy Thomas Hughes | July 7, 20263 High-Yield Dividend Stocks With Real Capital Gains Potential in 2026By Chris Markoch | July 6, 2026As Employers Drop Obesity Drug Coverage, Hims & Hers Could Be the WinnerBy Jessica Mitacek | July 6, 2026Abivax: Wall Street Catches Up to the DataBy Chris Markoch | July 7, 2026Vertex’s Crinetics Deal Balances Growth with Integration RiskBy Chris Markoch | July 8, 2026PLX, DSGN, DRUG, and CLYM Company DescriptionsClimb Bio NASDAQ:CLYM$12.84 +0.08 (+0.63%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$12.82 -0.02 (-0.12%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Climb Bio Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Climb Bio Inc., formerly known as Eliem Therapeutics Inc., is based in WELLESLEY, Mass.Bright Minds Biosciences NASDAQ:DRUG$71.33 +0.04 (+0.06%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$71.13 -0.20 (-0.28%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.Design Therapeutics NASDAQ:DSGN$11.78 +0.15 (+1.29%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$11.77 -0.01 (-0.08%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.Protalix BioTherapeutics NYSE:PLX$2.37 0.00 (0.00%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$2.37 +0.00 (+0.13%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/20- 07/24 Telecom Earnings Reveal a Sector That Finally Looks Healthier AMD and Cerbras Create A New Blueprint For Hardware Intel Earnings Reveal Whether the Chip Selloff Created a Buy CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test Defense Earnings Show Readiness Now and Modernization Ahead Freeport McMoRan Post-Earnings: Why Good Enough May Finally Be Good Enough Tesla Just Delivered Record Sales—So Why Did the Stock Sell Off? Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
